Lode Denolf

Lode Denolf

Auto-generated profile, based on publicly available information

Lode Denolf

Department of Biomolecular Medicine Ghent University Belgium

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2025 in EMBO Reports
Verified
Journal Article
Open access
JSJose Salguero-Linares
Jose Salguero-Linares
LALaia Armengot
Laia Armengot
JAJoel Ayet
Joel Ayet
NRNerea Ruiz-Solaní
Nerea Ruiz-Solaní
SSSvenja C Saile
Svenja C Saile
NCNúria S. Coll
Núria S. Coll
Plants utilize cell surface-localized pattern recognition receptors (PRRs) and intracellular nucleotide-binding leucine-rich repeat (NLR) receptors to detect non-self and elicit robust immune responses. Fine-tuning the homeostasis of these receptors is critical to prevent their hyperactivation. Here, we show that Arabidopsis plants lacking metacaspase 1 ( At MC1) display autoimmunity dependent on immune signalling components downstream of NLR and PRR activation. Overexpression of a catalytically inactive At MC1 in an atmc1 background triggers severe autoimmunity partially dependent on the same immune signalling components. Overexpression of the E3 ligase SNIPER1, a master regulator of NLR homeostasis, fully reverts the AtMC1-dependent autoimmunity phenotype, inferring that a broad defect in NLR turnover may underlie the severe phenotype observed. Catalytically inactive At MC1 localizes to punctate structures that are degraded through autophagy. Considering also previous evidence on the proteostatic functions of At MC1, we speculate that Wt At MC1 may either directly or indirectly control NLR protein levels, thereby preventing autoimmunity.

18 June 2025 in Molecular Oncology
Verified
Journal Article
Open access
NVNele Vandenbussche
Nele Vandenbussche
RIRenske Imschoot
Renske Imschoot
BLBéatrice Lintermans
Béatrice Lintermans
LDLode Denolf
Lode Denolf
JTJoachim Taminau
Joachim Taminau
Kathleen ClaesKathleen Claes
Kathleen Claes
Pancreatic cancer has a 5‐year survival rate of 12%, highlighting the need for reliable biomarkers for early detection and disease monitoring. Circulating tumor cells (CTCs) have emerged as a promising biomarker, yet their detection remains challenging. This study evaluates the Parsortix® system, a microfluidic device that enriches CTCs based on size and deformability, using pancreatic cancer cell lines. As increasing evidence indicates that during epithelial‐to‐mesenchymal transition (EMT) a cell's deformability increases, we evaluated possible biases by the device. The EMT stage of three pancreatic cancer cell lines, CAPAN‐1, MIA PaCa‐2, and PANC‐1, was assessed to classify them as epithelial, mesenchymal‐like, and hybrid, respectively. Spike‐in experiments showed that epithelial and hybrid phenotypes were more efficiently captured (62.6 ± 18.5% and 65.4 ± 11.1%) than mesenchymal‐like cancer cells (32.8 ± 10.2%). These results were confirmed using an EMT‐inducible breast cancer cell line. Lower recovery rates were found for the cells in a mesenchymal‐like state (31.5 ± 6.4%) than those in an epithelial state (47.56 ± 7.2%). In conclusion, the Parsortix® device may underestimate the number of mesenchymal CTCs.

7 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NVNele Vandenbussche
Nele Vandenbussche
RIRenske Imschoot
Renske Imschoot
BLBéatrice Lintermans
Béatrice Lintermans
LDLode Denolf
Lode Denolf
JTJoachim Taminau
Joachim Taminau
Kathleen ClaesKathleen Claes
Kathleen Claes
Pancreatic cancer has a 5-year survival rate of merely 12%. The high rate of late-stage diagnoses underscores the need for reliable biomarkers for early detection and disease monitoring. Circulating tumor cells (CTCs) have emerged as a promising biomarker, yet their detection remains challenging due to their rarity and phenotypic diversity. This study evaluates the Parsortix® system, a microfluidic device designed to enrich CTCs based on size and deformability, using pancreatic cancer cell lines. As increasing evidence indicates that during epithelial to mesenchymal transition (EMT) a cell’s deformability increases, we evaluated to what extent the Parsortix® system was biased towards epithelial cancer cells. First, the EMT stage of three pancreatic cancer cell lines, CAPAN-1, PANC-1 and MIA PaCa-2, was assessed using immunocytochemistry, flow cytometry and proteomics. CAPAN-1 cells were classified as epithelial, MIA PaCa-2 cells exhibited a mesenchymal-like phenotype, and PANC-1 cells demonstrated a hybrid phenotype. Then, by spiking these cells into blood samples, we determined the Parsortix® system’s ability to recover the cancer cells. Our results indicated that epithelial and hybrid phenotypes are more efficiently captured (62.6 ± 18.5% and 65.4 ± 11.1%) than mesenchymal cancer cells (32.8 ± 10.2%). To confirm these findings, spike-in experiments were repeated using an EMT inducible cell line. Again, significantly lower recovery rates were found for the cells in a mesenchymal-like state (31.5 ± 6.4%) compared to those in an epithelial state (47.56 ± 7.2%). In conclusion, the Parsortix® system may underestimate the presence of mesenchymal CTCs.